Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

megestrol

megestrol
  • Formulary
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Megace SUSPENSION, ORAL 40 mg/mL      
Megace ES SUSPENSION, ORAL 625 mg/5 mL    
Megace TABLET, ORAL 20 mg, 40 mg      
VIEW MORE Antineoplastic Agents
CLASS
100000
Comments:

ORDERED FORMULATION

FORMULARY INTERCHANGE

Megace ES

  • 625 mg/5 mL

 Megace

  • 800 mg/20 mL

Unit-dosed cups of Megace ES 625 mg/5 mL are no longer available on the market.

 

Reviewed: October 26, 2005 (MEGACE ES)

Updated: March 2022 (Megace ES)

Megestrol (Megace ES)

Last updated: Dec. 28, 2023
  • HAZ-MED: Group 1
  • Hormonal Therapy: This drug is a hormonal therapy in used in oncologic conditions. This drug may be resumed by a hospitalist or non-oncology healthcare provider without contacting an oncology pharmacy specialist or consulting an oncologist.






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved